Market News AIOpen the app

Corcept Therapeutics says the ADA and EASD recommend screening for hypercortisolism in their new diabetes report.

MarketRead the original at fidelity.com
Good for CORT

The new screening advice could help doctors find more people with excess cortisol, which fits Corcept's therapy focus. The report does not say those patients will use Corcept's medicines, so sales gains are not established.

CORT · Corcept Therapeutics Incorporated

AI read · Good for CORT

The AI's read

That may make excess cortisol easier to spot in people whose diabetes is hard to manage. Corcept focuses on therapies that change cortisol's effects, so more identified patients could broaden its potential reach. The report does not say doctors will prescribe Corcept's medicines or that sales have changed.

Get alerts for CORT

Follow Corcept Therapeutics Incorporated (CORT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CORT
Free on the App Store and Google Play, or on the web.